Acadia Pharmaceuticals (ACAD) Capital Expenditures (QoQ) (2012 - 2026)
Powered by 
Analysis
Acadia Pharmaceuticals (ACAD) Capital Expenditures (QoQ) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Acadia Pharmaceuticals | 4.82 Bn | 3.86 Bn | 279.64 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.36% |
| Mar 31, 2026 | 30.14% |
| Dec 31, 2025 | 932.22% |
| Sep 30, 2025 | 30.64% |
| Dec 31, 2024 | 547.14% |
| Jun 30, 2021 | -95.82% |
| Mar 31, 2021 | -46.17% |
| Dec 31, 2020 | 16.15% |
| Sep 30, 2020 | -41.32% |
| Jun 30, 2020 | 214.03% |
| Mar 31, 2020 | 351.21% |
| Dec 31, 2019 | 158.75% |
| Sep 30, 2019 | 300.00% |
| Jun 30, 2019 | -97.57% |
| Mar 31, 2019 | 56.27% |
| Dec 31, 2018 | -48.18% |
| Sep 30, 2018 | 782.61% |
| Jun 30, 2018 | -74.33% |
| Mar 31, 2018 | 6,300.00% |
| Dec 31, 2017 | -87.50% |